CRH Medical (CRH) Gets a Buy Rating from TD Securities
CRH Medical (CRH), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Lennox Gibbs from TD Securities remains bullish on the stock and has a C$5.50 price target.
According to TipRanks.com, Gibbs is ranked #4229 out of 5127 analysts.
Read also: Aphria (APHA) Stock Soars on C$2.8 Billion Takeover Offer, But Analysts See More Value
The the analyst consensus on CRH Medical is currently a Moderate Buy rating.
The company has a one-year high of C$5.91 and a one-year low of C$3.09. Currently, CRH Medical has an average volume of 190K.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Tuesday at C$4.28.